Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran.
Conclusion: According to WHO-recommended thresholds for interpreting cost-effectiveness, introduction of PCV-13 for children under 5 years in the Islamic Republic of Iran would be cost-effective. PMID: 31774134 [PubMed - in process]
Publication date: Available online 21 September 2020Source: European Journal of RadiologyAuthor(s): Mohammad Hossein Tabatabaei Seyed, Rahimi Habibollah, Moghaddas Fahimeh, Rajebi Hamid
Publication date: Available online 21 September 2020Source: Academic RadiologyAuthor(s): Alireza Zali, Mohammad-Reza Sohrabi, Ali Mahdavi, Nastaran Khalili, Morteza Sanei Taheri, Ali Maher, Mohammadmehdi Sadoughi, Afshin Zarghi, Seyed Ali Ziai, Abbas Arjmand Shabestari, Mehrdad Bakhshayeshkaram, Hamidreza Haghighatkhah, Babak Salevatipour, Alireza Abrishami, Masoomeh Raoufi, Pooneh Dehghan, Arash Khameneh Bagheri, Reza Jalili Khoshnoud, Khatereh Hanani
US drugmaker Johnson&Johnson says the vaccine could be available for use by early 2021 if proven safe, effective. In the next phase J&J will enroll up to 60,000 volunteers across three continents and study safety and efficacy of a single vaccine dose.
Johnson&Johnson has advanced its one-shot COVID-19 vaccine into phase 3 testing. The National Institute of Allergy and Infectious Diseases describes this as the fourth candidate to reach this stage.Medscape Medical News
Unlike some of its competitors, Johnson&Johnson ’s vaccine does not need to be frozen and may require just one shot instead of two.
Dr. Anthony S. Fauci and three other top U.S. health officials steering the government ’s virus response told senators that they would take a vaccine approved by the F.D.A. Johnson&Johnson announced that it plans to enroll 60,000 people in its Phase 3 vaccine trial.
In this study, we compared the immunogenicity and protective efficacy of CMFO subunit vaccines against primary progressive TB in two different adjuvant systems: the MTO oil-in-water (O/W) emulsion composed of monophosphoryl lipid A (MPL), trehalose-6,60-dibehenate (TDB), and oil in water emulsion MF59 and the DMT liposome containing dimethyldioctadecylammonium bromide (DDA), monophosphoryl lipid A (MPL), and trehalose-6,60-dibehenate (TDB). Our results demonstrated that the DMT-adjuvanted CMFO could confer more significant protection against M. tuberculosis infection than the CMFO/MTO did in mice. In particular, the adjuva...
Publication date: Available online 21 September 2020Source: The LancetAuthor(s): Enrico Bucci, Konstantin Andreev, Anders Björkman, Raffaele Adolfo Calogero, Ernesto Carafoli, Piero Carninci, Paola Castagnoli, Andrea Cossarizza, Cristina Mussini, Philippe Guerin, Brian Lipworth, Gianluca Sbardella, Teresa Stocki, Loretta Tuosto, Christoffer van Tulleken, Antonella Viola
CONCLUSION: Introducing PCV13 as part of Mongolia's national programme appears to be highly cost-effective when compared to no vaccination and cost-saving from a societal perspective at vaccine purchase prices offered through Gavi. Notwithstanding uncertainties around some parameters, cost-effectiveness of PCV introduction for Mongolia remains robust over a range of conservative scenarios. Availability of high-quality national data would improve future economic analyses for vaccine introduction. PMID: 28109706 [PubMed - as supplied by publisher]
Suárez VJ Abstract OBJECTIVE: To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine (PCV10) versus the 13-valent PCV (PCV13) to the National Immunization Schedule in Peru for prevention of pneumococcal disease (PD) in children